Moderna
MRNA,
+3.81%
and Pfizer
PFE,
-0.41%
have not yet started clinical trials for the new COVID-19 shots that are expected to better target the BA.4 and BA.5 strains of the virus. It has long been expected that the COVID-19 vaccines need to be reformulated to better protect against curre …
